紫杉醇纳米制剂在肿瘤免疫中应用的研究进展  

Paclitaxel nanoparticles and tumor immunotherapy:research advances

作　　者：张海燕 顾永卫 武鑫 陈建明[1] ZHANG Hai-yan;GU Yong-wei;WU Xin;CHENG Jian-ming(Teaching and Research Section of Pharmaceutics,School of Pharmacy,Fujian University of Traditional Chinese Medicine,Fuzhou 350108,China;Shanghai Weier Laboratory,Shanghai 201712,China)

机构地区：[1]福建中医药大学药学院药剂学教研室,福州350108 [2]上海维洱实验室,上海201712

出　　处：《国际药学研究杂志》2020年第10期793-797,共5页Journal of International Pharmaceutical Research

基　　金：国家自然科学基金资助项目(81772749);上海市青年科技启明星计划资助项目(18QB1400400);上海科技小巨人工程项目(1902HX76600);上海青浦区产学研合作发展资金资助项目(青产学研2019-5)。

摘　　要：紫杉醇是一种抗微管药物,通过抑制细胞有丝分裂和促进肿瘤细胞凋亡发挥抗肿瘤作用。但因其低溶解性、高毒性和低生物利用度等问题在临床上应用受限。纳米载体在药物递送中具有独特的优势,包括提高药物溶解度、延长药物循环时间、降低系统毒性、将药物靶向递送至肿瘤部位等。由于紫杉醇纳米制剂独特的结构和功能还对免疫系统产生影响,并表现出免疫调节特性。本文综述了紫杉醇纳米制剂对髓源性抑制性细胞、巨噬细胞、树突状细胞、自然杀伤细胞、效应T细胞、调节性细胞等免疫细胞的影响,及其在肿瘤免疫中的临床应用进展。Paclitaxel is an anti-microtubule drug,which exerts the anti-tumor effect by inhibiting mitosis and promoting tumor cell apoptosis.However,paclitaxel is restricted in the clinical application because of its low solubility,high toxicity and low bioavailability.Nano-carriers have unique advantages in drug delivery,including improving drug solubility,increasing drug cycle time,reducing systemic toxicity,targeting drugs to tumor sites.Due to the unique structure and function,the paclitaxel nano-preparation also has an impact on the immune system,and shows immunomodulatory characteristics.This paper reviews the effects of paclitaxel nano-preparation on myeloid-derived suppressor cells,macrophages,dendritic cells,natural killer cells,effector T cells,regulatory cells and other immune cells,as well as its clinical application in tumor immunology.

关 键 词：紫杉醇 纳米制剂 免疫细胞 肿瘤免疫 

分 类 号：R96[医药卫生—药理学]